ACRS Relative Valuation
ACRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACRS is overvalued; if below, it's undervalued.
Historical Valuation
Aclaris Therapeutics Inc (ACRS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.54. The fair price of Aclaris Therapeutics Inc (ACRS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.98
Fair
-5.45
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Aclaris Therapeutics Inc. (ACRS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.07. The thresholds are as follows: Strongly Undervalued below -6.59, Undervalued between -6.59 and -3.83, Fairly Valued between 1.70 and -3.83, Overvalued between 1.70 and 4.46, and Strongly Overvalued above 4.46. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.94
EV/EBIT
Aclaris Therapeutics Inc. (ACRS) has a current EV/EBIT of -1.94. The 5-year average EV/EBIT is -4.14. The thresholds are as follows: Strongly Undervalued below -14.44, Undervalued between -14.44 and -9.29, Fairly Valued between 1.01 and -9.29, Overvalued between 1.01 and 6.16, and Strongly Overvalued above 6.16. The current Forward EV/EBIT of -1.94 falls within the Historic Trend Line -Fairly Valued range.
33.89
PS
Aclaris Therapeutics Inc. (ACRS) has a current PS of 33.89. The 5-year average PS is 72.31. The thresholds are as follows: Strongly Undervalued below -52.28, Undervalued between -52.28 and 10.01, Fairly Valued between 134.60 and 10.01, Overvalued between 134.60 and 196.89, and Strongly Overvalued above 196.89. The current Forward PS of 33.89 falls within the Historic Trend Line -Fairly Valued range.
-6.34
P/OCF
Aclaris Therapeutics Inc. (ACRS) has a current P/OCF of -6.34. The 5-year average P/OCF is -89.17. The thresholds are as follows: Strongly Undervalued below -677.17, Undervalued between -677.17 and -383.17, Fairly Valued between 204.84 and -383.17, Overvalued between 204.84 and 498.84, and Strongly Overvalued above 498.84. The current Forward P/OCF of -6.34 falls within the Historic Trend Line -Fairly Valued range.
-4.80
P/FCF
Aclaris Therapeutics Inc. (ACRS) has a current P/FCF of -4.80. The 5-year average P/FCF is -7.14. The thresholds are as follows: Strongly Undervalued below -17.36, Undervalued between -17.36 and -12.25, Fairly Valued between -2.02 and -12.25, Overvalued between -2.02 and 3.09, and Strongly Overvalued above 3.09. The current Forward P/FCF of -4.80 falls within the Historic Trend Line -Fairly Valued range.
Aclaris Therapeutics Inc (ACRS) has a current Price-to-Book (P/B) ratio of 2.51. Compared to its 3-year average P/B ratio of 1.84 , the current P/B ratio is approximately 36.25% higher. Relative to its 5-year average P/B ratio of 4.12, the current P/B ratio is about -39.14% higher. Aclaris Therapeutics Inc (ACRS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -37.02%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -24.66% , the current FCF yield is about -100.00% lower.
2.72
P/B
Median3y
1.84
Median5y
4.12
-14.28
FCF Yield
Median3y
-37.02
Median5y
-24.66
Competitors Valuation Multiple
The average P/S ratio for ACRS's competitors is 0.00, providing a benchmark for relative valuation. Aclaris Therapeutics Inc Corp (ACRS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -24.09%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ACRS increased by 21.37% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -174.55 to -442.98.
The secondary factor is the Revenue Growth, contributed -24.09%to the performance.
Overall, the performance of ACRS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aclaris Therapeutics Inc (ACRS) currently overvalued or undervalued?
What is Aclaris Therapeutics Inc (ACRS) fair value?
How does ACRS's valuation metrics compare to the industry average?
What is the current P/B ratio for Aclaris Therapeutics Inc (ACRS) as of Dec 05 2025?
What is the current FCF Yield for Aclaris Therapeutics Inc (ACRS) as of Dec 05 2025?
What is the current Forward P/E ratio for Aclaris Therapeutics Inc (ACRS) as of Dec 05 2025?